94 related articles for article (PubMed ID: 23048192)
1. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease.
Sharma S; Farrington K; Kozarski R; Christopoulos C; Niespialowska-Steuden M; Moffat D; Gorog DA
Eur Heart J; 2013 Feb; 34(5):354-63. PubMed ID: 23048192
[TBL] [Abstract][Full Text] [Related]
2. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.
Saraf S; Christopoulos C; Salha IB; Stott DJ; Gorog DA
J Am Coll Cardiol; 2010 May; 55(19):2107-15. PubMed ID: 20447533
[TBL] [Abstract][Full Text] [Related]
3. Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention.
Christopoulos C; Farag M; Sullivan K; Wellsted D; Gorog DA
Thromb Haemost; 2017 Feb; 117(3):457-470. PubMed ID: 28004059
[TBL] [Abstract][Full Text] [Related]
4. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of troponin T and homocysteine in patients with end-stage renal disease.
Sahinarslan A; Güz G; Okyay K; Mutluay R; Yalçin R; Bali M; Sindel S; Cengel A
Turk Kardiyol Dern Ars; 2008 Sep; 36(6):382-7. PubMed ID: 19155641
[TBL] [Abstract][Full Text] [Related]
6. Significantly reduced spontaneous thrombolytic activity in older men: a possible explanation for the gender differences in risk of acute coronary syndromes.
Yamashita T; Sato A; Ikarugi H; Inoue A; Kitamori K; Ishii H; Yamamoto J
Thromb Res; 2005; 116(2):127-31. PubMed ID: 15907527
[TBL] [Abstract][Full Text] [Related]
7. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease.
Peralta CA; Shlipak MG; Fan D; Ordoñez J; Lash JP; Chertow GM; Go AS
J Am Soc Nephrol; 2006 Oct; 17(10):2892-9. PubMed ID: 16959827
[TBL] [Abstract][Full Text] [Related]
8. Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study.
Bejan-Angoulvant T; Bergerot C; Juillard L; Mezergues A; Morelon E; Pouteil-Noble C; André-Fouët X; Angoulvant D
Nephrol Dial Transplant; 2012 Jul; 27(7):2886-91. PubMed ID: 22344775
[TBL] [Abstract][Full Text] [Related]
9. Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease.
Darlington A; Ferreiro JL; Ueno M; Suzuki Y; Desai B; Capranzano P; Capodanno D; Tello-Montoliu A; Bass TA; Nahman NS; Angiolillo DJ
Thromb Haemost; 2011 Jul; 106(1):67-74. PubMed ID: 21655674
[TBL] [Abstract][Full Text] [Related]
10. PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease.
Rosser G; Tricoci P; Morrow D; Christopoulos C; Niespialowska-Steuden MN; Kozarski R; Wilcox R; Gorog DA
J Thromb Thrombolysis; 2014 Nov; 38(4):423-9. PubMed ID: 24676931
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study.
Amabile N; Guérin AP; Tedgui A; Boulanger CM; London GM
Nephrol Dial Transplant; 2012 May; 27(5):1873-80. PubMed ID: 22036944
[TBL] [Abstract][Full Text] [Related]
12. Screening for significant coronary artery disease in high-risk renal transplant candidates.
Gowdak LH; de Paula FJ; César LA; Martinez Filho EE; Ianhez LE; Krieger EM; Ramires JA; de Lima JJ
Coron Artery Dis; 2007 Nov; 18(7):553-8. PubMed ID: 17925609
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality.
Matsubara K; Suliman ME; Qureshi AR; Axelsson J; Martola L; Heimbürger O; Barany P; Stenvinkel P; Lindholm B
Blood Purif; 2008; 26(3):284-90. PubMed ID: 18421213
[TBL] [Abstract][Full Text] [Related]
14. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
15. Renal artery stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral artery disease.
Amighi J; Schlager O; Haumer M; Dick P; Mlekusch W; Loewe C; Böhmig G; Koppensteiner R; Minar E; Schillinger M
Eur J Clin Invest; 2009 Sep; 39(9):784-92. PubMed ID: 19522837
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis.
Hocher B; Liefeldt L; Quaschning T; Kalk P; Ziebig R; Godes M; Relle K; Asmus G; Stasch JP
J Am Soc Nephrol; 2007 Apr; 18(4):1323-30. PubMed ID: 17314326
[TBL] [Abstract][Full Text] [Related]
17. Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial.
Zoungas S; Lui M; Kerr PG; Teede HJ; McNeil JJ; McGrath BP; Polkinghorne KR
Intern Med J; 2011 Dec; 41(12):825-32. PubMed ID: 20298505
[TBL] [Abstract][Full Text] [Related]
18. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
19. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
[TBL] [Abstract][Full Text] [Related]
20. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study.
Kessler M; Zannad F; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P;
Nephrol Dial Transplant; 2007 Dec; 22(12):3573-9. PubMed ID: 17611249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
